Disease activity in patients with multiple sclerosis treated with alemtuzumab due to a pregnancy desire

被引：0
|
作者：
Tagliani, P. [1 ]
Vidal-Jordana, A. [2 ]
Zabalza, A. [2 ]
Arrambide, G. [2 ]
Rodriguez-Acevedo, B. [2 ]
Rio, J. [2 ]
Galan, I. [2 ]
Castillo, J. [3 ]
Midaglia, L. [4 ]
Cobo Calvo, A. [2 ]
Comabella, M. [2 ]
Nos, C. [2 ]
Auger, C. [5 ]
Rovira, A. [5 ]
Sastre-Garriga, J. [5 ]
Tintore, M. [2 ]
机构：
[1] Vall dHebron Inst Recerca, Barcelona, Spain
[2] Vall dHebron Univ Campus, Dept Neurol Neuroimmunol, Multiple Sclerosis Ctr Catalonia Cemcat, Barcelona, Spain
[3] Neuroimmunol & Multiple Sclerosis Unit Girona, Girona, Spain
[4] Vall Hebron Univ Hosp, Multiple Sclerosis Ctr Catalonia Cemcat, Dept Neurol Neuroimmunol, Barcelona, Spain
[5] Vall Hebron Univ Hosp, Barcelona, Spain
来源：
MULTIPLE SCLEROSIS JOURNAL | 2020年 / 26卷 / 3_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1119
引用
收藏
页码：647 / 647
页数：1
相关论文
共 50 条
  • [1] Disease activity during pregnancy and pregnancy outcomes in patients with multiple sclerosis treated with Alemtuzumab - A case series from the German MS and Pregnancy Registry
    Hellwig, Kerstin
    Ziemssen, Tjalf
    Rosenkranz, Thorsten
    Thiel, Sandra
    Limmroth, Volker
    Faiss, Juergen
    van Loh, Ina
    Loos, Ralf
    Lassek, Chrstoph
    Klemm, Claudia
    Goetze, Rainer
    Emrich, Peter
    Wessels, Carina
    Pernauer, Magdalena
    Wagner, Bert
    Gold, Ralf
    Gerbershagen, Kathrin
    NEUROLOGY, 2017, 88
  • [2] Disease activity during pregnancy and pregnancy outcomes in patients with multiple sclerosis (MS) treated with alemtuzumab - A case series from the German MS and pregnancy registry
    Gerbershagen, K.
    Thiel, S.
    Limmroth, V.
    Faiss, J.
    Van Loh, I.
    Loos, R.
    Gold, R.
    Hellwig, K.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 436 - 436
  • [3] Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab
    Ines Gaitan, Maria
    Celica Ysrraelit, Maria
    Correale, Jorge
    JAMA NEUROLOGY, 2017, 74 (09) : 1143 - 1144
  • [4] Thyroid dysfunction in multiple sclerosis patients treated with alemtuzumab
    Scott, J.
    Mahmud, M.
    Wheatley, T.
    Fisniku, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 858 - 858
  • [5] Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series
    Russo Cinzia Valeria
    Lanzillo Roberta
    Saccà Francesco
    Moccia Marcello
    Carotenuto Antonio
    Brescia Morra Vincenzo
    Neurological Sciences, 2021, 42 : 3427 - 3430
  • [6] Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series
    Valeria, Russo Cinzia
    Roberta, Lanzillo
    Francesco, Sacca
    Marcello, Moccia
    Antonio, Carotenuto
    Vincenzo, Brescia Morra
    NEUROLOGICAL SCIENCES, 2021, 42 (08) : 3427 - 3430
  • [7] Pregnancy Outcomes in Alemtuzumab Treated Women with Multiple Sclerosis: A Case Series
    Russo, Cinzia Valeria
    Lanzillo, Roberta
    Carotenuto, Antonio
    Moccia, Marcello
    Bresciamorra, Vincenzo
    Sacca, Francesco
    ANNALS OF NEUROLOGY, 2021, 90 : S177 - S178
  • [8] Pregnancy effect on disease activity in women with multiple sclerosis treated with cladribine
    Signoriello, E.
    Foschi, M.
    Lanzillo, R.
    Frau, J.
    Cocco, E.
    Borriello, G.
    Ianniello, A.
    Trotta, M.
    Landi, D.
    Maniscalco, G. T.
    Ruscica, F.
    Toscano, S.
    Patti, F.
    Zanghi, A.
    D'Amico, E.
    Fantozzi, R.
    Centonze, D.
    Lus, G.
    Bonavita, S.
    JOURNAL OF NEUROLOGY, 2024, 271 (07) : 4039 - 4045
  • [9] Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
    Saarela, Mika
    Senthil, Keerthi
    Jones, Joanne
    Tienari, Pentti J.
    Soilu-Hanninen, Merja
    Airas, Laura
    Coles, Alasdair
    Saarinen, Jukka T.
    NEUROLOGY, 2018, 90 (18) : 849 - 851
  • [10] Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis
    Buonomo, Antonio Riccardo
    Zappulo, Emanuela
    Viceconte, Giulio
    Scotto, Riccardo
    Borgia, Guglielmo
    Gentile, Ivan
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (07) : 709 - 717
12345